JANX008

About Janux Therapeutics

Janux Therapeutics is on a mission to transform cancer and autoimmune disease treatment by developing precision-engineered, tumor-activated immunotherapies that maximize efficacy and safety. Founded in 2017, the company has rapidly advanced its proprietary TRACTr and TRACIr platforms, moving multiple programs into clinical development and securing high-value partnerships with Merck and Bristol Myers Squibb. Its strategy centers on solving the critical therapeutic index challenge in immuno-oncology, aiming to expand the utility of potent T-cell redirecting therapies into solid tumors, a vast and underserved market.

Therapeutic Areas

Other EGFR-positive Solid Tumors Drugs